Table 1.
Baseline characteristics of study subgroups based on the median value of initial tacrolimus C/D ratio.
| Parameter | Tacrolimus C/D Ratio | p | |
|---|---|---|---|
| Slow Metabolizers ≥1.48 n = 61 |
Fast Metabolizers <1.48 n = 61 |
||
| Patient | |||
| Age (years) | 51.6 (48.5–54.7) | 44.7 (41.6–47.9) | <0.01 |
| Sex (M/F) | 40/21 | 36/25 | 0.46 |
| BMI (kg/m2) | 25.6 (24.5–26.8) | 25.7 (24.6–26.8) | 0.95 |
| Dialysis vintage (months) * | 34 (25–55) | 31 (20–44) | 0.29 |
| Residual diuresis (mL) * | 300 (0–1000) | 500 (100–1500) | 0.35 |
| Transplant procedure | |||
| Retransplant (n, %) | 4 (6.6) | 10 (16.4) | 0.09 |
| HLA class I mismatch * | 2 (2–3) | 2 (2–3) | 0.48 |
| HLA class II mismatch * | 1 (0–1) | 1 (0–1) | 0.09 |
| CIT (h) | 18.7 (16.9–20.4) | 17.8 (16.2–19.4) | 0.46 |
| Induction therapy | |||
| IL-2RB (n, %) | 29 (47.5) | 46 (75.4) | <0.01 |
| ATG (n, %) | 32 (52.3) | 15 (24.6) | |
| DGF (n, %) | 19 (31.1) | 9 (14.8) | <0.05 |
| Early acute rejection (n, %) | 5 (8.2) | 5 (8.2) | 1.0 |
| Tacrolimus dosing and metabolism | |||
| Tacrolimus dose (mg/d) * | 7.0 (4.0–12.0) | 11.0 (8.0–13.0) | <0.001 |
| Tacrolimus dose per kg (mg/kg) * | 0.11 (0.06–0.14) | 0.14 (0.12–0.16) | <0.001 |
| Initial tacrolimus level (ng/mL) * | 15.5 (9.0–21.6) | 9.7 (6.4–12.0) | <0.001 |
| Initial tacrolimus level > 15 ng/mL (%) | 50.8 | 13.1 | <0.001 |
| Tacrolimus C/D ratio * | 2.00 (1.71–2.50) | 0.99 (0.74–1.24) | <0.001 |
Data presented as means with 95% confidence interval, * medians with Q1–Q3 values or frequencies, as appropriate. C/D, concentration-to-dose; BMI, body mass index; HLA, human leukocyte antigen; CIT, cold ischemia time; IL-2RB, interleukin-2 receptor blocker; ATG, antithymocyte globulin; DGF, delayed graft function.